 |
|
|
|
 |
|
|
| Article 1 to 6 out of 6 concerning Amylin Pharmaceuticals, Inc.
|
-
Amylin Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
(05/07/2008)
Amylin Pharmaceuticals, Inc. announced the initiation of a Phase 2B clinical study evaluating various dosing combinations of pramlintide, an analog of the natural hormone amylin, and recombinant human leptin (r-metHuLeptin; metreleptin) for the ...
-
Amylin: FDA approves SYMLIN Pen-Injector devices offering convenience and accuracy for SYMLIN use
(10/04/2007)
Amylin Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the SymlinPen(TM) 120 and the SymlinPen(TM) 60 pen-injector devices for administering SYMLIN(R) (pramlintide acetate) injection. These pre-filled ...
-
Data shows that Amylin-Leptin co-administration reduces body weight and body fat
(06/13/2006)
Amylin Pharmaceuticals, Inc. announced study results showing that co-administration of two neurohormones known to have a role in body weight control, amylin (produced by beta cells in the pancreas) and leptin (produced by fat cells), resulted in ...
-
Amylin Pharmaceuticals Acquires Facility in Ohio to Manufacture Exenatide LAR
(01/03/2006)
Amylin Pharmaceuticals, Inc. announced that it has purchased an existing 150,000 square foot building and 26 acres of land in West Chester, Ohio. This acquisition completes previously announced facility expansion plans for the eventual commercial ...
-
Amylin Pharmaceuticals Files Preliminary Prospectus Supplement for Public Offering of Common Stock
(01/20/2005)
Amylin Pharmaceuticals, Inc. announced that it has filed a preliminary prospectus supplement to its shelf registration statement with the Securities and Exchange Commission relating to a proposed underwritten public offering of 6.5 million shares of ...
-
Amylin Pharmaceuticals Withdraws Swiss Regulatory Application for SYMLIN(R)
(01/08/2004)
SAN DIEGO, Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced receipt of correspondence from the Swiss Agency for Therapeutic Products (Swissmedic) indicating that SYMLIN(R) could not be approved for marketing in Switzerland based on data ...
|
|
|
|
|
Top